SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                   FORM 10-QSB

                 Quarterly Report Under Section 13 or 15 (d) of
                         Securities Exchange Act of 1934

                         For Period ended June 30, 2004

                         Commission File Number 0-32835


                          SAN JOSE INTERNATIONAL, INC.
             (Exact name of registrant as specified in its charter)


        DELAWARE                                        33-0956433
(State of Incorporation)                    (I.R.S. Employer Identification No.)


       Suite 1500, 800 West Pender Street, Vancouver B.C. Canada, V6C 2V6
               (Address of Principal Executive Offices) (Zip Code)


                                 (780) 708-0495
              (Registrant's telephone number, including area code)

Check whether the registrant  (1) has filed all reports  required to be filed by
Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding
12 months (or for such shorter  period that the  registrant was required to file
such reports), and (2) has been subject to such filing requirements for the past
90 days. Yes [X]  No [ ]

There were 23,996,512 shares of Common Stock outstanding as of June 30, 2004.

Authorized share capital of the registrant at June 30, 2004:  100,000,000 common
shares, par value of $0.0001, 20,000,000 preferred shares, par value $0.0001

The Company recorded $nil revenue for the quarter ended June 30, 2004.
<PAGE>
                           FORWARD-LOOKING STATEMENTS


THIS QUARTERLY REPORT ON FORM 10-QSB CONTAINS PREDICTIONS, PROJECTIONS AND OTHER
STATEMENTS ABOUT THE FUTURE THAT ARE INTENDED TO BE "FORWARD-LOOKING STATEMENTS"
WITHIN THE MEANING OF SECTION 21E OF THE  SECURITIES  EXCHANGE  ACT OF 1934,  AS
AMENDED (COLLECTIVELY, "FORWARD-LOOKING STATEMENTS"). FORWARD-LOOKING STATEMENTS
INVOLVE  RISKS AND  UNCERTAINTIES.  A NUMBER OF  IMPORTANT  FACTORS  COULD CAUSE
ACTUAL  RESULTS  TO  DIFFER   MATERIALLY  FROM  THOSE  IN  THE   FORWARD-LOOKING
STATEMENTS. IN ASSESSING FORWARD-LOOKING  STATEMENTS CONTAINED IN THIS QUARTERLY
REPORT ON FORM  10-QSB,  READERS  ARE  URGED TO READ  CAREFULLY  ALL  CAUTIONARY
STATEMENTS  - INCLUDING  THOSE  CONTAINED  IN OTHER  SECTIONS OF THIS  QUARTERLY
REPORT ON FORM 10-QSB.  AMONG SAID RISKS AND  UNCERTAINTIES IS THE RISK THAT THE
COMPANY WILL NOT SUCCESSFULLY  EXECUTE ITS BUSINESS PLAN, THAT ITS MANAGEMENT IS
ADEQUATE TO CARRY OUT ITS BUSINESS PLAN AND THAT THERE WILL BE ADEQUATE  CAPITAL
OR THEY MAY BE UNSUCCESSUFL FOR TECHNICAL, ECONOMIC OR OTHER REASONS.


                         PART I - FINANCIAL INFORMATION

ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS

                                                                     Page Number
                                                                     -----------

        Balance Sheets................................................... 3

        Statement of Operations.......................................... 4

        Statement of Stockholder's Equity................................ 5

        Statements of Cash Flows......................................... 6

        Notes to the Consolidated Financial Statements................... 7-11

                                       2
<PAGE>
                          SAN JOSE INTERNATIONAL, INC.
                          (A Development Stage Company)
                           Consolidated Balance Sheets
--------------------------------------------------------------------------------
<TABLE>
<CAPTION>
                                                                                As                 As
                                                                             June 30,         September 30,
                                                                               2004               2003
                                                                             --------           --------
                                                                           (Unaudited)         (Audited)
<S>                                                                          <C>                <C>
                                     ASSETS

Current Assets
  Cash                                                                       $     --           $     20
                                                                             --------           --------
Total Current Assets                                                               --                 20
                                                                             --------           --------

      TOTAL ASSETS                                                           $     --           $     20
                                                                             ========           ========

                  LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)

Current Liabilities
  Accounts payable                                                           $ 40,287           $     --
                                                                             --------           --------
Total Current Liabilities                                                      40,287                 --

      TOTAL LIABILITIES                                                        40,287                 --

Stockholders' Equity (Deficit)
  Preferred stock, ($.0001 par value, 20,000,000 shares authorized:
   none issued and outstanding)                                                    --                 --
  Common stock ($.0001 par value, 100,000,000 shares authorized:
   23,996,512 and 56,281,500 shares issued and outstanding as
   of June 30, 2004 and September 30, 2003, respectively)                       2,400              5,628
  Additional paid-in capital                                                   13,260             10,032
  Deficit accumulated during development stage                                (55,947)           (15,640)
                                                                             --------           --------
Total Stockholders' Equity (Deficit)                                          (40,287)                20
                                                                             --------           --------
       TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)                    $     --           $     20
                                                                             ========           ========
</TABLE>

                       See Notes to Financial Statements

                                       3
<PAGE>
                          SAN JOSE INTERNATIONAL, INC.
                          (A Development Stage Company)
                      Consolidated Statements of Operations
                                   (UNAUDITED)
--------------------------------------------------------------------------------
<TABLE>
<CAPTION>
                                                                                                 October 6, 1998
                                    Nine Months     Nine Months    Three Months    Three Months    (Inception)
                                      Ended           Ended           Ended           Ended          through
                                     June 30,        June 30,        June 30,        June 30,        June 30,
                                       2004            2003            2004            2003            2004
                                    -----------     -----------     -----------     -----------     -----------
<S>                                 <C>             <C>             <C>             <C>             <C>
Revenues
  Revenues                          $        --     $        --     $        --     $        --     $        --
                                    -----------     -----------     -----------     -----------     -----------
Total Revenues                               --              --              --              --              --

General & Administrative Expenses        40,307           3,821          39,201           1,475          55,947
                                    -----------     -----------     -----------     -----------     -----------
Total General & Administrative
 Expenses                                40,307           3,821          39,201           1,475          55,947
                                    -----------     -----------     -----------     -----------     -----------

Net Loss                            $   (40,307)    $    (3,821)    $   (39,201)    $    (1,475)    $   (55,947)
                                    ===========     ===========     ===========     ===========     ===========

Basic loss per share                $     (0.00)    $     (0.00)    $     (0.00)    $     (0.00)
                                    ===========     ===========     ===========     ===========
Weighted average number of
 common shares outstanding           52,378,919      56,281,500      48,476,338      56,281,500
                                    ===========     ===========     ===========     ===========
</TABLE>

                       See Notes to Financial Statements

                                       4
<PAGE>
                          SAN JOSE INTERNATIONAL, INC.
                          (A Development Stage Company)
           Consolidated Statement of Changes in Stockholders' Equity
             From October 6, 1998 (inception) through June 30, 2004
                                   (UNAUDITED)
--------------------------------------------------------------------------------
<TABLE>
<CAPTION>
                                                                                           Deficit
                                                                                         Accumulated
                                                                 Common     Additional     During
                                                    Common       Stock       Paid-in     Development
                                                    Stock        Amount      Capital        Stage        Total
                                                    -----        ------      -------        -----        -----
<S>                                                <C>          <C>          <C>          <C>          <C>
Beginning balance                                         --    $     --     $     --     $     --     $     --

Stock issued for cash on October 6, 1998           1,650,000         165         (155)                       10

Stock issued for cash on October 9, 1998           2,722,500         272         (107)                      165

Stock issued for cash on October 10, 1998            198,000          20          100                       120

Stock issued for services on December 1, 1998      9,900,000         990        2,010                     3,000

Net loss, October 6, 1998 (inception)
to September 30, 1998                                                                       (3,000)      (3,000)
                                                 -----------    --------     --------     --------     --------
Balance, September 30, 1998                       14,470,500       1,447        1,848       (3,000)         295
                                                 ===========    ========     ========     ========     ========
Stock issued for cash on April 7, 1999               561,000          56          284           --          340

Net loss, September 30, 1999                                                                  (444)        (444)
                                                 -----------    --------     --------     --------     --------
Balance, September 30, 1999                       15,031,500       1,503        2,132       (3,444)         191
                                                 ===========    ========     ========     ========     ========
Stock issued for cash on September 30, 2000       41,250,000       4,125          875                     5,000

Net loss, September 30, 2000                                                                    --           --
                                                 -----------    --------     --------     --------     --------
Balance, September 30, 2000                       56,281,500       5,628        3,007       (3,444)       5,191
                                                 ===========    ========     ========     ========     ========
Net loss, September 30, 2001                                                                (3,108)      (3,108)
                                                 -----------    --------     --------     --------     --------
Balance, September 30, 2001                       56,281,500       5,628        3,007       (6,552)       2,083
                                                 ===========    ========     ========     ========     ========
Net loss, September 30, 2002                                                                (4,231)      (4,231)
                                                 -----------    --------     --------     --------     --------
Balance, September 30, 2002                       56,281,500       5,628        3,007      (10,783)      (2,148)
                                                 ===========    ========     ========     ========     ========
Contributed capital                                                             7,025                     7,025

Net loss, September 30, 2003                                                                (4,857)      (4,857)
                                                 -----------    --------     --------     --------     --------
Balance, September 30, 2003                       56,281,500       5,628       10,032      (15,640)          20
                                                 ===========    ========     ========     ========     ========
Cancellation of shares June 8, 2004              (32,284,988)     (3,228)       3,228

Net loss, June 30, 2004                                                                    (40,307)     (40,307)
                                                 -----------    --------     --------     --------     --------
Balance, June 30, 2004                            23,996,512    $  2,400     $ 13,260     $(55,947)    $(40,287)
                                                 ===========    ========     ========     ========     ========
</TABLE>
                       See Notes to Financial Statements

                                       5
<PAGE>
                          SAN JOSE INTERNATIONAL, INC.
                          (A Development Stage Company)
                      Consolidated Statements of Cash Flows
                                   (UNAUDITED)
--------------------------------------------------------------------------------
<TABLE>
<CAPTION>
                                                                                                   October 6, 1998
                                             Nine Months   Nine Months  Three Months  Three Months   (Inception)
                                               Ended         Ended         Ended         Ended         through
                                              June 30,      June 30,      June 30,      June 30,       June 30,
                                                2004          2003          2004          2003           2004
                                              --------      --------      --------      --------       --------
<S>                                           <C>           <C>           <C>           <C>            <C>
CASH FLOWS FROM OPERATING ACTIVITIES
  Net income (loss)                           $(40,307)     $ (3,821)     $(39,201)     $ (1,475)      $(55,947)
  Increase (decrease) in accounts payable       40,287         3,731        39,201         1,445         40,287
  Common stock issued for services                  --            --            --            --          3,000
                                              --------      --------      --------      --------       --------
     Net cash provided by (used in)
      operating activities                         (20)          (90)           --           (30)       (12,660)

CASH FLOWS FROM INVESTING ACTIVITIES

     Net cash provided by (used in)
      investing activities                          --            --            --            --             --

CASH FLOWS FROM FINANCING ACTIVITIES
  Change in common stock                        (3,228)           --            --        (3,228)         1,410
  Change in paid in capital                      3,228            --            --         3,228         11,250
                                              --------      --------      --------      --------       --------
     Net cash provided by (used in)
      financing activities                          --            --            --            --         12,660
                                              --------      --------      --------      --------       --------

Net increase (decrease) in cash                    (20)          (90)           --           (30)            --

Cash at beginning of period                         20           146            --            86             --
                                              --------      --------      --------      --------       --------
Cash at end of period                         $     --      $     56      $     --      $     56       $     --
                                              ========      ========      ========      ========       ========

SUPPLEMENTAL DISCLOSURES OF CASH FLOW
INFORMATION:
  Interest paid                               $     --      $     --      $     --      $     --
                                              ========      ========      ========      ========
  Income taxes paid                           $     --      $     --      $     --      $     --
                                              ========      ========      ========      ========
</TABLE>

                       See Notes to Financial Statements

                                       6
<PAGE>
                          SAN JOSE INTERNATIONAL, INC.
                          (A Development Stage Company)
                   Notes to Consolidated Financial Statements
                                  June 30, 2004
                                   (UNAUDITED)


NOTE 1. ORGANIZATION AND DESCRIPTION OF BUSINESS

The Company was  incorporated on October 6, 1998, under the laws of the State of
Delaware,  as San  Jose  International,  Inc.  The  Company  has no  significant
revenues and no material operations and in accordance with SFAS # 7, the Company
is considered a development stage company.

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

A. PRINCIPLES OF CONSOLIDATION

These  consolidated  financial  statements  include  the  accounts  of San  Jose
International,   Inc.   and  its   wholly-owned   subsidiary,   GammaCan,   Ltd.
(collectively  "the  Company")  (See  Note  9).  All  significant  inter-company
accounts and transactions have been eliminated.

B. BASIS OF ACCOUNTING

The  financial  statements  have  been  prepared  using  the  accrual  basis  of
accounting.  Under the accrual  basis of  accounting,  revenues  are recorded as
earned and expenses  are  recorded at the time  liabilities  are  incurred.  The
Company has adopted a September 30, year-end.

C. USE OF ESTIMATES

The preparation of financial  statements in conformity  with generally  accepted
accounting principles requires management to make estimates and assumptions that
affect  the  reported  amounts  of assets  and  liabilities  and  disclosure  of
contingent  assets and  liabilities at the date of the financial  statements and
the  reported  amounts of revenues  and expenses  during the  reporting  period.
Actual results could differ from those estimates.

D. CASH EQUIVALENTS

The Company  considers  all highly  liquid  investments  with  maturity of three
months or less when purchased to be cash equivalents.

E. INCOME TAXES

Income taxes are provided in accordance  with Statement of Financial  accounting
Standards No. 109 (SFAS 109),  Accounting for Income Taxes. A deferred tax asset
or liability is recorded for all temporary differences between financial and tax
reporting and net operating loss  carryforwards.  Deferred tax expense (benefit)
results  from  the net  change  during  the  year of  deferred  tax  assets  and
liabilities.

                                       7
<PAGE>
                          SAN JOSE INTERNATIONAL, INC.
                          (A Development Stage Company)
                   Notes to Consolidated Financial Statements
                                  June 30, 2004
                                   (UNAUDITED)


NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT.)

E. INCOME TAXES (CONT.)

Deferred tax assets are reduced by a valuation allowance when, in the opinion of
management,  it is more likely than not that some portion of all of the deferred
tax assets will be realized.  Deferred tax assets and  liabilities  are adjusted
for the effects of changes in tax laws and rates on the date of enactment.

F. BASIC EARNINGS PER SHARE

In February  1997,  the FASB issued SFAS No. 128,  "Earnings  Per Share",  which
specifies the computation, presentation and disclosure requirements for earnings
(loss) per share for entities  with  publicly  held common  stock.  SFAS No. 128
supersedes the provisions of APB No. 15, and requires the  presentation of basic
earnings (loss) per share and diluted earnings (loss) per share. The Company has
adopted the provisions of SFAS No. 128 effective October 6, 1998 (inception).

Basic  earnings  (loss) per share  amount is computed by dividing the net income
(loss) by the weighted  average  number of common  shares  outstanding.  Diluted
earnings  (loss) per share is the same as basic earnings (loss) per share due to
the lack of dilutive items in the Company.

NOTE 3. WARRANTS AND OPTIONS

There are no warrants or options outstanding to acquire any additional shares of
common or preferred stock.

NOTE 4. GOING CONCERN

The accompanying  consolidated  financial statements have been prepared assuming
that the Company will  continue as a going  concern.  The Company has net losses
for the period  from  inception  (October  6,  1998)  through  June 30,  2004 of
$55,947.  This condition raises substantial doubt about the Company's ability to
continue as a going concern.  The Company's  continuation  as a going concern is
dependent on its ability to meet its obligations, to obtain additional financing
as may be required  and  ultimately  to attain  profitability.  These  financial
statements do not include any adjustments  that might result from the outcome of
this uncertainty.

                                       8
<PAGE>
                          SAN JOSE INTERNATIONAL, INC.
                          (A Development Stage Company)
                   Notes to Consolidated Financial Statements
                                  June 30, 2004
                                   (UNAUDITED)


NOTE 5. INCOME TAXES

                                                             As of June 30, 2004
                                                             -------------------
     Deferred tax assets:
     Net operating tax carryforwards                               $ 8,987
     Other                                                               0
                                                                   -------
     Gross deferred tax assets                                       8,987
     Valuation allowance                                            (8,987)
                                                                   -------

     Net deferred tax assets                                       $     0
                                                                   =======

Realization of deferred tax assets is dependent upon  sufficient  future taxable
income during the period that deductible temporary differences and carryforwards
are expected to be available to reduce  taxable  income.  As the  achievement of
required  future taxable income is uncertain,  the Company  recorded a valuation
allowance.

NOTE 6. SCHEDULE OF NET OPERATING LOSSES

     1998 Net Operating Loss                                       $ (3,000)
     1999 Net Operating Loss                                           (444)
     2000 Net Operating Income                                            0
     2001 Net Operating Loss                                         (3,108)
     2002 Net Operating Loss                                         (4,231)
     2003 Net Operating Loss                                         (4,857)
     2004 Net Operating Loss  (six months)                          (40,307)
                                                                   --------

     Net Operating Loss                                            $(55,947)
                                                                   ========

As of June 30,  2004,  the  Company has a net  operating  loss  carryforward  of
approximately  $ 55,947,  which will  expire 20 years from the date the loss was
incurred.

                                       9
<PAGE>
                          SAN JOSE INTERNATIONAL, INC.
                          (A Development Stage Company)
                   Notes to Consolidated Financial Statements
                                  June 30, 2004
                                   (UNAUDITED)

NOTE 7. RELATED PARTY TRANSACTIONS

The Company's neither owns nor leases any real or personal property.  A director
without  charge  provides  office  services.  Such costs are  immaterial  to the
financial  statements and,  accordingly,  have not been reflected  therein.  The
officers and directors of the Company are involved in other business  activities
and may, in the future,  become involved in other business  opportunities.  If a
specific business opportunity becomes available, such persons face a conflict in
selecting  between the Company and their other business  interests.  The Company
has not formulated a policy for the resolution of such conflicts.

See Note 9.

NOTE 8. STOCK TRANSACTIONS

Issuance of Stock:

On October 6, 1998, the Company issued 1,650,000 shares of common stock for cash
of $10.00.

On October 9, 1998, the Company issued 2,722,500 shares of common stock for cash
of $165.00.

On October 10, 1998,  the Company issued 198,000 shares of common stock for cash
of $120.00.

On December 1, 1998,  the Company  issued  9,900,000  shares of common stock for
services valued at $3,000.00.

On April 7, 1999,  the Company issued 561,000 shares of common stock for cash of
$340.00.

On September 30, 2000, the Company issued  41,250,000 shares of common stock for
cash of $5,000.00.

On June 8, 2004,  the Company's  sole  Director  returned  32,284,988  shares of
common stock to the treasury for cancellation.

As of June 30, 2004 the Company had 23,996,512 shares of common stock issued and
outstanding.

On April 20, 2004 the Company's sole director declared a 16.5 to 1 forward stock
split of its  Common  Stock.  All shares  have been  retroactively  restated  to
reflect the 16.5 to 1 stock split.

                                       10
<PAGE>
                          SAN JOSE INTERNATIONAL, INC.
                          (A Development Stage Company)
                   Notes to Consolidated Financial Statements
                                  June 30, 2004
                                   (UNAUDITED)


NOTE 9. TRANSACTION WITH ARP BIOMED, LTD.

During June,  2004 the Company  entered into an agreement with ARP Biomed,  Ltd.
("ARP") of Israel to acquire all of ARP's interest in research and  development,
patents and intellectual  property,  to provide  clinical  treatment for various
cancer types. The intellectual  property being acquired  includes patents in the
United States and certain other  countries,  pending patents in other countries,
know-how,  trial protocols,  manuscripts,  and certain  material  contracts (the
"Intellectual Property").

The Company is acquiring the Intellectual  Property through Gammacan,  Ltd., its
wholly owned subsidiary.  12.5% of the shares of Gammacan with a deemed value of
$100,000  will  be  issued  to ARP as  consideration  for  the  purchase  of the
Intellectual  Property on closing.  The Company will own the remaining  87.5% of
Gammacan.  Under the terms of the  agreement,  the  Company is also  required to
raise  $800,000 and lend those funds to Gammacan,  which will use those funds to
commence  clinical  trials and further  research and  development  utilizing the
Intellectual Property.

Closing of the  acquisition of the  Intellectual  property is contingent,  among
other things,  upon  provision of the financing  before  September 1, 2004,  and
completion of a suitable employment agreement with a key individual.

Additionally,  the Company's  former sole Director sold 699,996 of his shares to
this key individual in a private transaction.

NOTE 10. SUBSEQUENT EVENT

On July 5, 2004, the Company's  Director adopted a resolution  changing the name
of the Company to GammaCan  International Inc. The name change was approved by a
majority of stockholders  on July 8, 2004, but is subject to certain  regulatory
review and filings.

                                       11
<PAGE>
ITEM 2.   MANAGEMENT'S PLAN OF OPERATION

San Jose  International,  Inc. was  incorporated  under the laws of the state of
Delaware on October 6, 1998.  Our fiscal year end is September 30. Our shares of
Common  Stock are quoted in the United  States on the  National  Association  of
Securities  Dealers Over the Counter  Bulletin Board (the "OTCBB") and effective
June 7, 2004, concurrent with the forward split of our shares (SEE PART II, ITEM
2), quoted for trading with the symbol "SJOS".

We currently  have no revenue from  operations,  we are in a start-up phase with
our existing assets and we have no significant  assets,  tangible or intangible.
There can be no assurance that we will generate  revenues in the future, or that
we will be able to operate profitably in the future, if at all. We have incurred
net losses in each fiscal year since inception of our operations.

We have never had any bankruptcy,  receivership,  or similar proceedings, or any
material  reclassification,  merger,  consolidation  or  purchase  of  sale of a
significant amount of assets in the ordinary course of business.

Initially,  our  business  plan was to focus on the  business of  marketing  and
selling custom-designed Spanish colonial doors, windows, frames and related door
hardware.  We were planning to sell our products to the home building  industry.
During the fourth  quarter of our last fiscal year,  it became  apparent that we
could not readily attract  additional  financing for our proposed  business.  We
currently  have  minimal  assets and no capital  resources  to proceed  with our
business plan. These  circumstances have  significantly  impacted our ability to
develop a successful business plan around these products. As an alternative,  we
undertook  initiatives  to  identify  alternative  businesses  that  may be more
receptive  to the  financial  markets  and more  likely  to  achieve  profitable
operations.

During our first  quarter  ended  December 31, 2003,  we  identified a promising
business prospect focused on the seismic acquisition business located in Western
Canada and agreed in principal to acquire all of the shares of two Alberta based
companies. On April 20, 2004, we decided to terminate our efforts to pursue this
proposed  acquisition,  because  it  appeared  we  would  not be  successful  in
obtaining the necessary financing on a timely basis.

NEW BUSINESS OPPORTUNITY

On June 21, 2004 we announced that we signed an agreement with ARP Biomed,  Ltd.
("ARP") of Israel to acquire all of ARP's interest in research and  development,
patents and intellectual  property,  to provide  clinical  treatment for various
forms of cancer.  The intellectual  property being acquired  includes patents in
the  United  States  and  certain  other  countries,  pending  patents  in other
countries,   know-how,  trial  protocols,   manuscripts,  and  certain  material
contracts (the "Intellectual Property").

We are acquiring the Intellectual Property through Gammacan,  Ltd., a subsidiary
we created specifically for this purpose. 12.5% of the shares of Gammacan with a
deemed value of $100,000 will be issued to ARP as consideration for the purchase
of the Intellectual  Property.  We will own the remaining 87.5%. In addition, we
have agreed to raise $800,000 and lend those funds to Gammacan,  which will then
commence  clinical  trials and further  research and  development  utilizing the

                                       12
<PAGE>
INTELLECTUAL PROPERTY

Gammacan  is  planning  to  focus  on the  commercialization  of an  anti-cancer
immunotherapy  that appears to be effective in reducing the metastatic spread of
a wide  range of  cancers.  GammaCan's  treatment  will be based on  intravenous
immunoglobulin or IVIG, a safe, non-toxic human plasma-based product,  currently
used to treat a variety of immune  deficiencies  and  autoimmune  diseases,  and
replace the antibodies in people who are unable to produce them.  Antibodies are
a naturally occurring,  disease fighting protein or compound produced by healthy
people.  Intravenous  implies  the direct  injection  or  delivery,  via certain
equipment, into the patient's bloodstream.  In preliminary studies, IVIG appears
to boost and strengthen  cancer  patient's  immune  systems or antibody  levels,
which may be successful in fighting cancer.  Although there can be no assurance,
many experts  currently view IVIG as a promising  future  alternative to today's
standard chemotherapy.

CLOSING OF THE ACQUISITION OF THE INTELLECTUAL  PROPERTY FROM ARP IS CONTINGENT,
AMONG OTHER THINGS DESCRIBED HEREIN, UPON OUR AB ILITY TO SUCCESSFULLY RAISE THE
$800,000  BEFORE  SEPTEMBER 1, 2004.  THE DISCUSSION  NOTED BELOW  REGARDING OUR
PROPOSED  CANCER  TREATMENT  BUSINESS  AND OUR PLAN OF OPERATION IS BASED ON THE
ASSUMPTION WE CLOSE WITH ARP.  HOWEVER,  AT THIS STAGE THERE CAN BE NO ASSURANCE
THAT WE WILL BE SUCCESSFUL IN OUR EFFORTS TO CONCLUDE THIS TRANSACTION.

CURRENT CANCER STATISTICS

Cancer is a disease of the body's cells.  Cells in all the tissues and organs of
the body  constantly  grow and  divide  to  replace  old and  damaged  cells and
maintain  the  health of the body.  Normally,  all cells  divide  and  reproduce
themselves in an orderly and controlled manner. In cancer,  however,  some cells
keep dividing without proper control,  forming a lump (which is called a primary
tumour).  In leukaemia,  or cancer of the blood,  too many white blood cells are
produced.

Sometimes cancer cells break away from a tumour and travel to other parts of the
body through the  bloodstream or lymphatic  system.  (The lymphatic  system is a
network of fine channels - called lymph vessels - which run  throughout the body
and are part of the body's protection  against  infection and cancer).  When the
cancer  cells reach other parts of the body they may settle and start to develop
into new tumours. These are known as secondary cancers/tumors or metastases.

There are  approximately  2.5 million cases of cancer diagnosed each year in the
Western  world alone.  Primary  tumors,  while still  localized,  can be treated
through surgery and radiation.  However, cancers tend to metastasize, or spread,
and form secondary tumors in other locations  throughout the body. Most existing
therapeutics or treatments fail because the cancer has  metastasized  and formed
multiple tumors.  At present,  nearly 40% of cancer victims with operable tumors
ultimately   succumb  to  metastatic  or  spreading  cancer  following  surgery.
Frequently, metastasis is triggered by the surgical operation itself. During the
course of surgery,  malignant cells may become dislodged from the tumor mass and
enter the circulatory system thus increasing the chance of spreading cancer.

                                       13
<PAGE>
The extent to which  metastases  occur  varies  with the type of primary  tumor.
Melanoma or skin cancer,  breast cancer, lung cancer,  colon cancer and prostate
cancer are among the types of cancer that frequently metastasize or spread. When
metastasis  takes place,  the secondary  tumors may form at a number of sites in
the body.  Lungs,  liver,  brain and bone are the most common sites of secondary
tumors.

CURRENT CANCER TREATMENTS

Current cancer treatments include surgery,  radiation,  and chemotherapy.  These
treatments  can be  ineffective  because they are either unable to target cancer
cells throughout the body or they give rise to serious and life-threatening side
effects.  Consequently,  the medical  community is still a long way from winning
the war on cancer. Companies which can provide winning anti-cancer drugs that at
least partially overcome the limitations of current cancer treatments are likely
to be well  received by the medical  establishment  and to achieve a  leadership
position in the cancer drug market.

The   current   alternative   to  the  above   noted  is  the  use  of   various
immunotherapies.  Current efforts to deliver  effective  cancer  immunotherapies
generally  fall into three  categories:  cytokines,  monoclonal  antibodies  and
vaccines.  Cytokines are medical  drugs that  stimulate the immune system during
infections.  Drug  developers  have  hoped  that the  same  factors  that  fight
infections could be used to combat cancer cells.  Several have been approved for
commercial use, but are generally limited in their application.

Many  companies  are involved in  developing  monoclonal  antibodies,  which are
designed to bind to specific cancer cells and target them for destruction by the
immune system.  These products are generally more developed,  in terms of market
use and  acceptance,  than  cytokines and several have  significant  sales.  The
products realizing significant sales generally have limited or few side effects.

Cancer vaccines rely on the administration of tumor antigens to elicit an immune
response  that remains  after the vaccine  itself has  disappeared.  Most cancer
vaccine products currently being developed require the harvesting and processing
of tumor cells to make custom  vaccines for each  patient.  Though this approach
has shown promise in clinical  trials,  scaling-up  manufacture  is likely to be
problematic, and these vaccines are generally considered to be a number of years
away from commercial use.

CHEMOTHERAPY

Chemotherapy is the use of anti-cancer drugs to destroy cancer cells.  There are
over 50 different  chemotherapy drugs and some are given on their own, but often
several drugs may be combined.  The type of  chemotherapy  treatment given for a
particular cancer depends on many things, the type of disease, where in the body
it started,  what the cancer  cells look like under the  microscope  and whether
they have spread to other parts of the body.

Chemotherapy is currently the standard treatment for cancer that has or may have
metastasized  or  spread.   Chemotherapy  is  a  systemic   treatment,   usually
administered  intravenously,  but can be administered a number of ways, intended
to kill  cancer/tumor  cells,  which have  spread to  multiple  sites.  However,
chemotherapy  may also kill healthy dividing cells and  consequently,  may cause

                                       14
<PAGE>
serious side effects.  These side effects may include a weakening of a patient's
immune system,  and reduction in number of white blood cells which are necessary
to combat  bacterial  infections,  inhibition  or  slowing of bone  marrow  cell
growth,  which also may be  accompanied  with slow down in the production of red
blood cells or anemia, the inability to form blood clots,  diarrhea,  nausea and
hair loss.  Generally,  these side  effects are  temporary  in nature,  but most
patients experience a significant degree of discomfort,  and can be long term in
some cases.

Chemotherapy can fail to completely eradicate micro-metastases, or the spreading
of very small cancer  tumors,  already  residing in remote organs (lung,  liver,
bone  marrow  or  brain),  especially  when  treatment  is  discontinued  due to
patients'  inability  to  tolerate  its  side  effects.  If  the  cancer  is not
completely eradicated, it will likely continue to grow.

The need for an effective,  non-toxic  treatment to inhibit spreading cancers is
widely recognized and numerous  researchers,  biotechnology  and  pharmaceutical
companies are seeking  alternatives to chemotherapy  drugs.  The potential for a
large receptive commercial market exists for a successful approach to inhibiting
spreading cancers without causing serious side effects.

IVIG OR INTRAVENOUS IMMUNOGLOBIN

Our proposed  immunotherapy  product, if ultimately proven to be successful on a
regulatory and commercial  basis,  aims to harness the body's immune system,  or
its natural defense mechanism to destroy cancer cells.

Immunoglobulins  or IVIG is a type of protein found in human blood that helps to
fight  off  harmful  bacteria,   viruses  and  other  germs.  IVIG  is  a  blood
plasma-derived  product containing protective antibodies normally present in the
blood of healthy  individuals.  IVIG is used to replace the antibodies in people
who are  unable to produce  them,  thereby  restoring  an almost  normal  immune
response and helping to prevent or reduce the severity of certain infections. It
is widely used in the treatment of certain  autoimmune  diseases.  Extensive use
over a period of years has demonstrated  that IVIG therapy is a safe,  non-toxic
therapy with virtually no side effects.

Currently,  approximately  twenty  companies  produce IVIG  products,  achieving
worldwide sales of about $500 million annually.  These companies manage pools of
1,000 to 20,000 blood donors who are carefully  screened  prior to being allowed
to give blood.  This donated  plasma is also  extensively  tested for  pathogens
prior to use. It is this donated blood plasma that is used to manufacture  IVIG,
and through the  combining  the blood plasma of many  individual  donors,  it is
believed that the resulting combination provides superior therapy than IVIG from
one individual exclusively.

The  largest  producers  of IVIG  for the  U.S.  market  are  ZLB  Bioplasma  (a
subsidiary  of  the  Australian   blood  products   company  CSL  Ltd.),   Alpha
Therapeutics, Baxter Healthcare, Bayer Biological Products and Aventis Behring.

IVIG products became commercially  available in the early 1980's.  There are six
indications or uses approved by the U.S. Food and Drug Administration (FDA), but
IVIG is also used to treat over seventy other "off-label"  conditions  supported
by a  consensus  of  expert  opinion,  mostly  primary  immune  deficiencies  or
autoimmune  neuromuscular  disorders.  Between 40% and 50% of IVIG prescriptions
are written for  off-label  indications.  Patients  receiving  IVIG  therapy for
primary immune deficiencies usually receive the therapy for life, while patients

                                       15
<PAGE>
receiving   IVIG   therapy  for   autoimmune   disorders   receive  the  therapy
intermittently over a period of months, and sometimes years,  depending on their
condition.

IVIG is generally considered to be an expensive therapy, because it is a natural
product  manufactured from whole human blood. A typical dose may consist of five
consecutive  days of  intravenous  administration  of 2 grams  per  kilogram  of
patients'  body weight.  The price of one gram of IVIG has recently  ranged from
$18 to $25 on the wholesale level.  For a 150 pound (68.2 kilogram)  individual,
this  translates  into a price of between  $2,455 and $3,410 for a full two gram
per kilogram  body-weight  round of treatment.  The cost of  administration in a
hospital,  is also  considerable and the total cost for a round of treatment can
thus range from $8,500 to $20,000 per treatment.

PRE-CLINICAL AND PRELIMINARY EXPERIMENTS

ARP's scientists have already conducted  certain animal  experiments to test the
effectiveness of IVIG  immunotherapy  in treating  cancer,  and investigated the
effectiveness  of IVIG treatment at various stages of disease  progression  with
varying  dosages  and  routes of  administration.  They  have  made  preliminary
progress in  understanding  the  mechanisms  under  which IVIG  appears to fight
cancer.

While these experiments showed promising results,  they are preliminary.  Use of
IVIG in a commercial  setting would be subject to much further  substantial  and
significant  testing, and subject to certain clinical trials required by the FDA
and similar regulatory bodies in other countries.

At this stage  however,  there can be no assurance  that IVIG will evolve into a
successful  commercial  product,  gain  acceptance  for  general use or use as a
replacement for existing  therapeutic  products,  or even be approved for use by
the regulatory authorities.

These  early  experiments  have  shown  that IVIG  treatment  appears  to reduce
metastases and tumor recurrence for a broad spectrum of cancers,  with virtually
no side effects. However, much more testing must be completed. IVIG also appears
to show promise to increase the chances for long term recovery by preventing the
return and spread of cancer.  These preliminary  experiments have also indicated
that IVIG therapy  holds promise as an effective  anti-cancer  treatment at much
lower doses than is commonly used for treating immune  deficiencies.  This would
serve to make the treatment more affordable and may enable IVIG immunotherapy to
be used as a cancer prevention measure in high risk populations.

In these  preliminary  experiments,  IVIG  also  appears  to be  effective  when
administered  intravenously,  or through  several other methods of delivery into
the patient's body.  Alternative  routes of  administration  could  dramatically
improve  ease-of-use,  lower the delivered  price of treatments,  and enable the
treatment of additional conditions.

COMPETITION

Cancer  therapeutics  represents  a major  pharmaceutical  market  with  $12 -13
billion in worldwide sales in 2001. Between 1995 and 2000, the market grew at an
average  annual rate of 15-20%.  Average  annual  growth is forecast to be 8-10%

                                       16
<PAGE>
through 2015. Despite the large number of patients and the high medical need for
effective  treatments,  the cancer drug market is ranked only eighth in terms of
drug  sales.  This  corresponds  to 4.0% of the total  worldwide  pharmaceutical
market of $248  billion.  In  comparison,  the 2001  worldwide  drug  market for
cardiovascular  diseases  totaled $49 billion  (19.5%),  central  nervous system
diseases $41 billion  (16.5%),  and  alimentary/metabolism  diseases $38 billion
(15.3%).  The reason for the relatively  small size of the cancer drug market is
believed to be primarily due to the lack of effective, safe drugs.

The need for effective,  safe cancer drugs has been recently demonstrated by the
successful  introductions of new cancer drugs that are relatively  effective and
safe.  Rituxan(R),  for the treatment of certain  cancers,  was approved in late
1997. By 2002,  this product  achieved  sales of $1.57 billion.  Taxotere(R),  a
therapeutic product for the treatment of breast cancer and certain types of lung
cancer, was approved in 1996 and achieved sales of $1.35 billion in 2002.

Competition  in  the  area  of  biomedical  and   pharmaceutical   research  and
development is intense and significantly depends on scientific and technological
factors.  These factors include the  availability of patent and other protection
for  technology  and  products,  the  ability  to  commercialize   technological
developments  and the  ability  to obtain  governmental  approval  for  testing,
manufacturing  and  marketing.  Our Company will compete with other  specialized
biotechnology  and  pharmaceutical  firms  in  the  United  States,  Europe  and
elsewhere,  many of which are  significantly  larger  than our  Company and have
already  achieved  profitable  operations.  Many of these companies have focused
their development  efforts in the cancer therapeutics area. Many major companies
have also developed or acquired internal capabilities for product development or
made  commercial  arrangements  with other  biopharmaceutical  companies.  These
companies,  as well as academic institutions,  governmental agencies and private
research  organizations,  also  compete  with  our  Company  in  recruiting  and
retaining highly qualified scientific personnel and consultants.

Competition  within  this  sector  itself is  increasing,  so we will  encounter
competition  from existing  firms that offer  competitive  solutions in the same
disease  area.  These  competitive  companies  could  develop  products that are
superior  to,  or have  greater  market  acceptance,  than  the  products  being
developed  by our Company.  We will have to compete  against  other  biotech and
pharmaceutical  companies with greater market recognition and greater financial,
marketing and other resources.

INTELLECTUAL PROPERTY

Subsequent to closing with ARP, our Company,  through  GammaCan,  will enjoy the
patented  protection  of IVIG for treating  solid tumors  through two major U.S.
patents  (#5,562,902  and  #5,965,130),  and additional  U.S. and  international
patent  applications.  The latest US patent was on  registered  on October 1999.
Patent  coverage  includes  a wide  range of issues  such as: a novel  method of
administering  to a mammal a preparation of IVIG for inhibiting tumor metastasis
or spreading, for treating primary tumors, and for a broad spectrum of cancerous
diseases.  The IVIG  preparation to be administered  according to this invention
may contain intact or fragmented  immunoglobulin  molecules. The preparation may
be administered  intravenously,  directly under the skin or subcutaneous routes,
directly into a cavity (such as an organ or stomach),  either as a sole agent or
in combination with other agents or methods,  which are commonly used for cancer
treatment.

We  believe  anyone  selling  IVIG for  treatment  of cancer is subject to these
patents.

                                       17
<PAGE>
GOVERNMENT REGULATION - PRODUCT DEVELOPMENT AND COMMERCIAL USE

We will be using and developing  biotechnology and  pharmaceutical  products for
use in treating human  diseases.  We will be directly  affected by  governmental
regulations from the United States Food and Drug Administration  (FDA) for these
products.

The FDA regulates  clinical  development  and marketing  approval of all medical
products  intended for human use. The laws and  regulations of the FDA place the
burden of proof of safety and efficacy on the  manufacture of the product.  This
agency possesses extensive experience with its regulatory mechanisms and applies
them  to all  products,  with  differing  statutes  for  various  categories  of
products.  Other  countries  have  comparable  regulatory  agencies  to the FDA,
although the specific regulations may differ substantially.

The growth in this industry over the last several  decades has been  accompanied
by growth in the extent and complexity of the FDA statutes and regulations,  and
of the intensity of the FDA's  regulations  of the  development,  manufacturing,
distribution,  marketing, promotion,  advertising and use of regulated products.
In  the  last  decade,  the  FDA  legal  and  regulatory  obstacles  to  product
commercialization  and the penalties of non-compliance have been pivotal factors
in the success or failure of companies  in our  industry.  This is  particularly
true for  small,  emerging  companies  developing  biopharmaceuticals  and other
biotechnology products.

RISK FACTORS RELATED TO OUR PROPOSED ACQUISTION

You should carefully consider, in addition to the other information contained in
this  quarterly  report or in the  documents  incorporated  by reference  herein
(particularly  our 10KSB for September 30,  2003),  the following  risk factors,
SHOULD WE CLOSE WITH ARP:

WE WILL  REQUIRE A  SIGNIFICANT  AMOUNT OF  ADDITIONAL  CAPITAL TO  DEVELOP  AND
COMMERCIALIZE OUR PRODUCTS.

We will need to raise  additional  capital in order to finance  our  anticipated
losses as we  continue  to develop  IVIG.  We will also need to finance  capital
expenditures for equipment,  intellectual property and other asset acquisitions.
Our future  capital  requirements  may be  substantial,  and will depend on many
factors including:

     *    the duration and cost of our clinical trials
     *    the  progress  and scope of our other  collaborative  and  independent
          research, development and clinical projects
     *    the size and complexity of these programs
     *    the time and costs involved in seeking regulatory approvals
     *    the time and costs involved in developing,  maintaining  and expanding
          our manufacturing facilities
     *    our business development and commercialization strategy
     *    the costs  associated  with filing,  prosecution  and  enforcement  of
          patent claims

                                       18
<PAGE>
There can be no  assurance  that  capital  will be  available to us on favorable
terms, or at all. We may choose to raise  additional  capital from time to time,
either through public or private debt or equity  financings,  licensing or other
arrangements.  Any  additional  equity  financings  could  be  dilutive  to  our
shareholders  and debt financings,  if available,  may subject us to restrictive
covenants.  Any financing done through  licensing or other similar  arrangements
may require us to relinquish our rights to certain of our technologies, products
or marketing  territories.  Our failure to raise  capital when needed would harm
our business, financial condition and results of operations.

RISKS RELATED TO THE DEVELOPMENT AND COMMERCIALIZATION OF THE IVIG PRODUCT(S)

AT PRESENT,  OUR SUCCESS DEPENDS SOLELY ON THE SUCCESSFUL  COMMERCIALIZATION  OF
IVIG FOR OUR PROPOSED USE AS A CANCER THERAPY ALTERNATIVE.

The  successful  commercialization  of IVIG is  crucial  for our  success.  This
proposed product and its potential  application is in an early stage of clinical
and  manufacturing/process   development.  It  faces  a  variety  of  risks  and
uncertainties. Principally, these risks include the following:

     *    future clinical trial results may show that IVIG at effective doses is
          not well tolerated by the recipients or not efficacious as compared to
          placebo.
     *    future clinical trial results may be inconsistent  with ARP's previous
          preliminary  testing  results.  Data from our  earlier  studies may be
          inconsistent with clinical data.
     *    even if IVIG  is  shown  to be safe  and  effective  for its  intended
          purpose,  we  may  face  significant  or  unforeseen  difficulties  in
          obtaining/manufacturing  sufficient  quantities  at or  at  reasonable
          prices.
     *    our ability to complete the development and  commercialization of IVIG
          for our intended use is  significantly  dependent  upon our ability to
          obtain and maintain  experienced  and committed  partners to assist us
          with  obtaining  clinical  and  regulatory   approvals  for,  and  the
          manufacturing,  marketing  and  distribution  of IVIG  on a  worldwide
          basis.
     *    even  if  IVIG  products  are  successfully  developed,   commercially
          produced and receive all necessary regulatory  approvals,  there is no
          guarantee that there will be market acceptance.
     *    our competitors may develop therapeutics or other treatments which are
          superior  or less  costly  than  our own  with  the  result  that  our
          products,  even if they are successfully  developed,  manufactured and
          approved, may not generate significant revenues

If we are  unsuccessful  in dealing with any of these risks, or if we are unable
to successfully  commercialize our IVIG products for some other reason, it would
likely seriously harm our business.

OUR SUCCESS DEPENDS ON OUR ABILITY TO ATTRACT AND RETAIN COLLABORATIVE  PARTNERS
OVER WHOM WE HAVE LIMITED CONTROL.

Our business will likely depend on our ability to enter into  arrangements  with
corporate  and academic  collaborators  relating to the testing,  manufacturing,
marketing and commercialization of our products. If successful, we are intending
to license or sublicense that property to others. We are planning to try to have
our partners  assume the  obligation to  manufacture,  market and distribute the

                                       19
<PAGE>
resulting products. Consequently, our success depends upon our partners' ability
to  perform  these  tasks.  There  can be no  assurance  that we will be able to
establish  necessary  arrangements  on  favorable  terms,  or at  all,  or  that
collaborative agreements will be successful.

OUR SUCCESS DEPENDS ON OUR ABILITY TO PROTECT OUR PROPRIETARY RIGHTS AND OPERATE
WITHOUT INFRINGING UPON THE PROPRIETARY RIGHTS OF OTHERS.

We plan to continue to protect the technology that we consider  important to the
development of our business by filing United States and selected  foreign patent
applications.  We currently hold several patents and pending patent applications
in the United States and corresponding  patents and patent applications filed in
certain other countries over IVIG and its proposed use in cancer therapeutics.

The patent position of  biopharmaceutical  and biotechnology firms, is generally
uncertain  and  involves  complex  legal and factual  questions.  We do not know
whether  any of our  current or future  patent  applications  will result in the
issuance of any patents.  Even issued patents may be challenged,  invalidated or
circumvented.  Patents  may  not  provide  a  competitive  advantage  or  afford
protection against competitors with similar technology. Competitors or potential
competitors may have filed  applications  for, or may have received  patents and
may obtain  additional and proprietary  rights to compounds or processes used by
or competitive with ours. In addition,  laws of certain foreign countries do not
protect  intellectual  property  rights to the same extent as do the laws of the
United States or Canada.

Patent litigation is becoming  widespread in the  biotechnology  industry and we
cannot  predict how this will affect our  efforts to form  strategic  alliances,
conduct   clinical   testing  or  manufacture  and  market  any  products  under
development.  If  challenged,  our patents may not be held valid.  We could also
become  involved in  interference  proceedings in connection with one or more of
our patents or patent  applications  to determine  priority of invention.  If we
become  involved  in  any  litigation,   interference  or  other  administrative
proceedings,  we will likely incur  substantial  expenses and the efforts of our
technical and management personnel will be significantly  diverted. In addition,
an adverse determination could subject us to significant  liabilities or require
us to seek licenses that may not be available on favorable  terms, if at all. We
may be restricted or prevented  from  manufacturing  and selling our products in
the event of an adverse determination in a judicial or administrative proceeding
or if we fail to obtain necessary licenses.

Our commercial success will also depend  significantly on our ability to operate
without  infringing the patents and other  proprietary  rights of third parties.
Patent applications are, in many cases,  maintained in secrecy until patents are
issued.  The  publication of discoveries in the scientific or patent  literature
frequently  occurs  substantially  later  than the date on which the  underlying
discoveries  were  made and  patent  applications  are  filed.  In the  event of
infringement or violation of another  party's  patent,  we may be prevented from
pursuing product development or commercialization.

In addition to patents, we are planning to rely on trade secrets and proprietary
know-how to protect our  intellectual  property.  We are planning to require our
employees,   consultants,   outside   scientific   collaborators  and  sponsored
researchers and other advisors to enter into confidentiality  agreements.  These
agreements  may not provide  meaningful  protection or adequate  remedies in the

                                       20
<PAGE>
event of  unauthorized  use or disclosure  of our  proprietary  information.  In
addition,  it  is  possible  that  third  parties  could  independently  develop
proprietary  information  and  techniques   substantially  similar  to  ours  or
otherwise gain access to our trade secrets.

WE MAY NOT BE ABLE TO OBTAIN  REGULATORY  APPROVALS  THAT WILL BE  NECESSARY  TO
COMMERCIALIZE OUR PRODUCTS.

The manufacture and sale of therapeutic products in the United States and Canada
is governed by a variety of statutes and  regulations in both  countries.  These
laws govern the development,  testing,  manufacture,  safety,  efficacy,  record
keeping,  labelling,  storage,  approval,   advertising,   promotion,  sale  and
distribution  of  biopharmaceutical  products.  If our products  are  ultimately
marketed abroad,  they would also be subject to extensive  regulation by foreign
governments.  There  can be no  assurance  that we will  be able to  obtain  the
required  regulatory   approvals  or  comply  with  the  applicable   regulatory
requirements for any of our IVIG product(s) in development.  If we are unable to
obtain necessary regulatory  approvals,  we may not be able to commercialize our
products.

The  IVIG  product(s)  currently  under  development  will  require  significant
clinical testing and investment of significant funds prior to commercialization.
Securing  regulatory  approval requires us to submit extensive clinical data and
supporting  information for each indication to establish the product's efficacy.
The process of completing  these  processes is likely to take a number of years.
Any delay in obtaining approvals may:

     *    adversely  affect the successful  commercialization  of our product(s)
          that we develop
     *    diminish any competitive advantages that we may obtain
     *    adversely affect our receipt of revenues or royalties

Additionally,  if we fail to comply with applicable  regulatory  requirements at
any stage  during  the  regulatory  process,  we may be  subject  to  sanctions,
including fines,  suspensions,  product recalls,  production suspensions,  civil
penalties and criminal prosecution, among other actions.

EVEN IF WE ARE ABLE TO  COMMERCIALIZE  OUR  PRODUCTS,  OUR PRODUCTS MAY NOT GAIN
MARKET ACCEPTANCE.

Whether  or not any our  products  gain  market  acceptance  among  the  medical
community in general,  as well as the degree of market  acceptance of any of our
products, will depend on a number of factors, including:

     -    establishment and demonstration of clinical usefulness and safety
     -    cost-effectiveness of the products
     -    their potential advantage over alternative products
     -    reimbursement policies of governments and third-party payors
     -    marketing and distribution support for the products

The success of other products in our market segment in establishing  the market,
their  pricing,  their  clinical  usefulness  or other  potential  advantages or
disadvantages,  will  very  likely  have a major  impact on the  success  of our
product.  If our  products do not achieve  significant  market  acceptance,  our

                                       21
<PAGE>
business,  financial  condition  and results of  operations  will be harmed.  In
addition,   third-party   payors  such  as  government   health   administration
authorities, managed care providers and private health insurers are increasingly
challenging the price and examining the cost  effectiveness  of medical products
and services.  If these third-party payors fail to provide adequate coverage for
our products, the market acceptance of the products may be adversely affected.

COMPETITION  IN OUR  TARGETED  MARKETS  IS  INTENSE  AND  DEVELOPMENTS  BY OTHER
COMPANIES COULD RENDER OUR PRODUCTS OR TECHNOLOGIES NON-COMPETITIVE.

The biotechnology  industry is highly competitive and subject to significant and
rapid technological change.  Developments by other companies within the industry
could  render  our  products  or  technologies  non-competitive.  Some of  these
products may be more effective or have an entirely  different  approach or means
of accomplishing the desired effect than our products.  We expect  technological
competition from biotechnology  companies and academic research  institutions to
increase over time.

Many competitors and potential  competitors have  substantially  greater product
development  capabilities  and  financial,   scientific,   marketing  and  human
resources than we do. Our competitors may succeed in developing products earlier
and obtaining  regulatory approvals and patent protection for such products more
rapidly than we can.

OUR LACK OF COMMERCIAL MANUFACTURING EXPERIENCE MEANS THAT WE WILL HAVE TO INCUR
SUBSTANTIAL  COSTS TO DEVELOP  MANUFACTURING  FACILITIES  OR CONTRACT WITH THIRD
PARTIES OVER WHOM WE HAVE LIMITED CONTROL TO DEVELOP OUR PRODUCTS.

In order to be successful,  our products must be manufactured and/or obtained in
commercial  quantities  in  compliance  with  regulatory   requirements  and  at
acceptable  costs.  We do not have  facilities to  commercially  manufacture our
products under  development  and we must  initially  obtain the small amounts of
products we require for clinical studies from contract manufacturing  companies.
In order to manufacture our products in commercial  quantities,  we will need to
develop  manufacturing  facilities or contract with third parties to manufacture
our  products.  We may not be able to  develop  or  otherwise  secure  access to
appropriate facilities and manufacturing contracts with third parties may not be
available to us on favorable terms, if at all.

OUR LACK OF  MARKETING  AND  SALES  EXPERIENCE  MEANS  THAT WE MUST  RELY ON THE
EFFORTS OF OTHERS TO COMMERCIALIZE OUR PRODUCTS.

We do not have a marketing, sales or distribution capability. We intend to enter
into arrangements with third parties to market and sell most of our products. We
may not be able to enter into  marketing and sales  arrangements  with others on
favorable terms, if at all. To the extent that we enter into marketing and sales
arrangements  with other  companies,  our revenues will depend on the efforts of
others and which efforts may not be  successful.  If we are unable to enter into
satisfactory  third-party  arrangements,  then we must  develop a marketing  and
sales  force,  which may need to be  substantial  in size,  in order to  achieve
commercial  success for any product.  We may not successfully  develop or obtain
the necessary marketing and sales experience or have sufficient  resources to do
so. If we fail to establish  successful  marketing and sales  capabilities or to

                                       22
<PAGE>
enter into successful  marketing  arrangements with third parties, our business,
financial  condition  and results of  operations  will be  materially  adversely
affected.

OUR DEVELOPMENT  PROGRAMS AND FUTURE PRODUCTS  SUBJECT US TO THE RISK OF PRODUCT
LIABILITY  CLAIMS  FOR  WHICH WE MAY NOT BE ABLE TO  OBTAIN  ADEQUATE  INSURANCE
COVERAGE.

Human  therapeutic  products  involve the risk of product  liability  claims and
associated  adverse  publicity.   Currently,   our  principal  risks  relate  to
participants  in our  clinical  trials who may  become ill or suffer  unintended
consequences  from our IVIG  therapeutic.  If we  ultimately  are  successful in
commercializing  a  product,   claims  might  be  made  directly  by  consumers,
healthcare  providers or by pharmaceutical  companies or others selling or using
our  products.  There  can be no  assurance  that we will be able to  obtain  or
maintain  sufficient and affordable  insurance  coverage for any of these claims
and,  without  sufficient  coverage,  any claim brought  against us could have a
materially  adverse  effect on our business,  financial  condition or results of
operations.

OUR  BUSINESS MAY BE HARMED IF WE CANNOT  OBTAIN  SUFFICIENT  QUANTITIES  OF RAW
MATERIALS.

We will be dependent on outside  vendors for our entire  supply of IVIG.  If the
third party  suppliers  were to cease  production or otherwise fail to supply us
with quality IVIG and we were unable to contract on  acceptable  terms for these
services with alternative suppliers, our ability to produce our products, and to
conduct testing and clinical trials would be adversely affected.

IF WE ARE UNABLE TO ENROLL  SUFFICIENT  PATIENTS AND CLINICAL  INVESTIGATORS  TO
COMPLETE OUR  CLINICAL  TRIALS,  OUR  DEVELOPMENT  PROGRAMS  COULD BE DELAYED OR
TERMINATED.

The rate of completion of our clinical trials,  and those of our  collaborators,
is significantly  dependent upon the rate of enrollment of patients and clinical
investigators. Patient enrollment is a function of many factors, including:

     -    efforts of the  sponsor and  clinical  sites  involved  to  facilitate
          timely enrollment
     -    patient referral practices of physicians
     -    design of the protocol
     -    eligibility criteria for the study in question
     -    perceived risks and benefits of the drug under study
     -    the size of the patient population
     -    availability of competing therapies
     -    availability of clinical trial sites
     -    proximity of and access by patients to clinical sites

We may have  difficulty  obtaining  sufficient  patient  enrollment or clinician
participation  to conduct our  clinical  trials as  planned,  and we may need to
expend  substantial  additional  funds to obtain access to resources or delay or
modify our plans significantly. These considerations may lead us to consider the
termination  of  ongoing  clinical  trials or  development  of a  product  for a
particular indication.

                                       23
<PAGE>
OUR  COLLABORATIONS  WITH SCIENTIFIC  ADVISORS AND ACADEMIC  INSTITUTIONS MAY BE
SUBJECT TO RESTRICTION AND CHANGE.

We plan on working with scientific advisors and academic  collaborators who will
assist us in our ongoing research and development efforts. These scientists will
not  be  our  employees  and  may  have  other   commitments  that  limit  their
availability  to us. If a conflict of interest  arises between their work for us
and their work for another  entity,  we may lose their  services.  In  addition,
although we plan on our scientific advisors and academic  collaborators  signing
non-disclosure  agreements,  it is possible that valuable proprietary  knowledge
may become publicly known which would compromise our competitive advantage.

WE ARE SUBJECT TO INTENSE  COMPETITION FOR SKILLED PERSONNEL AND THE LOSS OF KEY
PERSONNEL OR THE  INABILITY  TO ATTRACT AND RETAIN  ADDITIONAL  PERSONNEL  COULD
IMPAIR OUR ABILITY TO CONDUCT OUR OPERATIONS.

We will be highly  dependent  on the  principal  members of our  management  and
scientific  staff,  the  loss of  whose  services  might  adversely  impact  the
achievement of our objectives and the  continuation of existing  collaborations.
In addition,  recruiting and retaining qualified scientific personnel to perform
future research and development  work will be critical to our success.  There is
currently a shortage of  employees  with  expertise in our areas of research and
clinical  and  regulatory  affairs,  and this  shortage  is likely to  continue.
Competition  for skilled  personnel is intense and turnover  rates are high. Our
ability to attract and retain qualified personnel may be limited.

ADDITIONAL RISKS RELATED TO OWNING OUR SHARES

OUR SHARE PRICE WILL LIKELY BECOME HIGHLY VOLATILE.

Factors such as  announcements  of  technological  innovations,  new  commercial
products, patents, the development of technologies (by us or others), results of
clinical studies, regulatory actions, publications,  financial results or public
concern  over the safety of our  products or other  related  products  and other
factors  could  have a  significant  effect on the  market  price of our  common
shares.

PLAN OF OPERATION

The following discussion of the financial condition, results of operations, cash
flows  and  changes  in  financial  position  of our  Company  should be read in
conjunction  with our most  recent  financial  statements  and  notes  appearing
elsewhere in this Form 10-QSB; and our Form 10KSB for September 30, 2003.

As of the date of filing of our 10Q for June 30,  2004,  we have not  closed the
transaction with ARP described in this report.  As noted herein,  the closing of
the  transaction  with  ARP is  subject  to our  Company  raising  $800,000  and
concurrently  lending it to  GammaCan  prior to  September  1, 2004.  It is also
subject to  completion  of a suitable  employment  agreement  with a certain key
individual, among other things.

If we cannot  close  this  transaction,  we do not  anticipate  making any major
purchases of capital  assets in the next 12 months,  or conducting  any research
and development  directly,  nor will we hire additional employees in the next 12
months.

                                       24
<PAGE>
This  foregoing  discussion  regarding  our  Plan of  Operation  is based on the
assumption we close with ARP.

CLINICAL TRIALS

GammaCan's initial focus over the next several years is to demonstrate  efficacy
of IVIG cancer  immunotherapy in human clinical trials.  Efficacy is the ability
of a drug or other  treatment  to produce the  desired  result when taken by its
intended  users.  If  ultimately  proven to be  successful,  and there can be no
assurance  that it  will  be,  GammaCan  could  be  well-positioned  to  enter a
licensing  agreement with a major  pharmaceutical  partner for commercial market
development and sales.

IVIG immunotherapy  will require  regulatory  approval before being commercially
marketed for human  therapeutic  use.  Clinical trials  generally  include three
phases  that  together  may take  several  years to  complete.  Phase I clinical
studies (toxicity trials) are primarily conducted to establish safety.  Phase II
studies are designed to determine  preliminary  efficacy.  Phase III studies are
conducted to optimize therapeutic efficacy in a statistically significant manner
at the levels of optimal dose,  method of delivery  into the body or route,  and
schedule of  administration.  Once clinical  trials are completed  successfully,
products may receive regulatory approval.

Subject to closing with ARP and raising  sufficient  capital,  GammaCan plans to
begin enrolling  patients within the quarter following  closing,  for a Phase II
study  using  IVIG  immunotherapy  as an adjunct  treatment  for a wide range of
cancers. Since IVIG is an established,  safe therapy, we will not be required to
conduct  Phase I studies.  Phase II clinical  trials will be conducted at two or
three  medical  centers in Israel.  It is  expected to take six months to enroll
patients.  We are planning on including  several different cancers in the trial,
some of which  metastasize and progress  quickly,  so statistically  significant
preliminary results may be available after one year. We will continue to monitor
patients  for at least  two  years.  If  successful  or  promising,  and at this
preliminary  stage there is no assurance they will be, results of these clinical
trials  will be used  to  enter  into  discussions  with a major  pharmaceutical
partner  to work  with  us to  potentially  commercialize  the  product(s)  (SEE
"Business Strategy).

GammaCan  estimates  that it will take about thirty months to complete Phase III
trials and receive regulatory  approval to market IVIG  immunotherapy.  In 2007,
when GammaCan  anticipates IVIG immunotherapy may be available  commercially for
treating cancer, provided the trials are successful,  clinical trial results and
applications  for the  product(s)  will be published.  These studies will enable
physicians  to  study  and  ultimately  prescribe  IVIG  therapy  for a range of
specific cancers. Subsequent post-marketing studies would then also be conducted
to further  evaluate  efficacy for  different  population  groups and  different
stages of disease progression.

GammaCan is also  planning  to conduct  additional  clinical  trials to test new
formulations of IVIG and to test IVIG  immunotherapies  for different cancers at
different  stages of disease  progression  with  varying  dosages  and routes of
administration.  GammaCan's goal is to partner with a pharmaceutical  company to
conduct  these  further  Phase II and  Phase  III  trials,  in  order to  attain
broad-based regulatory approval.

                                       25
<PAGE>
LONG TERM BUSINESS STRATEGY

As noted previously, if IVIG shows significant promise thorough clinical trials,
GammaCan plans to ultimately seek a strategic  commercial partner with extensive
experience  commercializing and marketing cancer drugs. It is envisaged that the
partner would be responsible to ensure that regulatory approvals are achieved in
a timely manner and that  GammaCan's IVIG  immunotherapies  penetrate the cancer
market rapidly following FDA approval.  This planned strategic partnership could
provide a marketing and sales  infrastructure for GammaCan's products as well as
financial and operational  support for global trials and other FDA  requirements
concerning future clinical development.  GammaCan's pharmaceutical partner could
also provide  capital and expertise that would enable the partnership to develop
new formulations of IVIG cancer immunotherapy suitable for patients at different
stages of disease progression.

GammaCan also plans to establish a close relationship with at least one producer
of IVIG  products  to  co-develop  new product  formulations  and to provide our
Company with IVIG for further pre-clinical testing and clinical trials. There is
considerable  expertise  involved in producing IVIG and significant  expense and
infrastructure involved in collecting and testing blood. Working together with a
partner in the industry will expedite new product  formulation,  production  and
ensure a safe standardized product.

OTHER RESEARCH AND DEVELOPMENT PLANS

In addition to conducting early-stage clinical trials, GammaCan plans to conduct
research to develop  alternative  delivery  systems,  to  determine  the optimal
dosage for different  patient groups and to investigate  alternative  sources of
immunoglobulin  other than human plasma.  GammaCan plans to conduct  research to
isolate  the  fraction of IVIG,  which is  responsible  for its  anti-metastasis
effects and to develop a synthetic  version of IVIG. These  formulations will be
suitable for:

     *    Low-dose,    preventative   therapy   for   disease-free,    high-risk
          individuals,
     *    Strong  dose for use in  conjunction  with  surgery  and other  cancer
          treatments, and
     *    Maintenance dose for use to prevent recurrence of cancer growth.

Our plan is to patent  any  successful  inventions  resulting  from our  further
research activities.

PERSONNEL

During the next 12 months,  if we close our  transaction  with ARP,  our company
plans to function with a small management staff of 3 persons.  During this time,
GammaCan  will focus on  managing  Phase II  clinical  trials  and  establishing
preliminary  relationships with potential  commercial  partners. A CEO, a senior
pharmaceutical  marketing  professional and a business development director will
be recruited. The subsidiary GammaCan will also hire a VP-Regulatory Affairs who
will be  responsible  for  coordinating  the clinical  trials and plan to hire a
Chief Medical Officer responsible for supervising the trials and assuring proper
patient  monitoring.  These two positions will initially be on a part-time basis
and will become  full-time  positions as  activities  expand in over the next 12
months.  We are also planning to hire a CFO on a part-time basis.  This position
will also become a full time  position in 2005.  Prof.  Shoenfeld,  a key person

                                       26
<PAGE>
involved in the development  and  preliminary  trials with IVIG, is intending to
serve as GammaCan's Chief  scientific  officer on a part-time basis. The Company
plans to hire additional  administrative  staff as needed.  Our CEO and CFO will
also function in the same positions in our GammaCan subsidiary.

FACILITIES

During the quarter,  we relocated our  operations to Suite 1500, 800 West Pender
Street,  Vancouver, B.C. Canada, V6C 2V6. We occupy less than 100 square feet on
a rent free basis.

Subsequent to closing the transaction  with ARP,  GammaCan plans to relocate and
establish office and laboratory  facilities of  approximately  150 square meters
(1,700  square feet)  within six months and to add another 250 square  meters of
space in 2006 or 2007 as the  Company  grows.  During  an  initial  period,  the
Company plans to rent small offices.

PLANNED EXPENDITURES

Our planned expenditures  (000's) for the next 12 months,  assuming we close the
ARP transaction include:

       R&D
           Salaries                               $   70
           Contract                                  200
           Clinical Trials                           400
           Patents and IP                             20
           Other                                     120

       Marketing
           Salaries                                  140
           Other                                     160

       General & Admin
           Salaries                                  150
           Consultants                                40
           Travel                                     50
           Professional fees                         180
          Office and other                           200
                                                  ------
       Total                                      $1,730
                                                  ======

THE $800,000 WE ARE REQUIRED TO RAISE TO CLOSE THE TRANSACTION  WITH ARP IS ONLY
SUFFICIENT  TO FUND OUR  PROPOSED  OPERATIONS  AND  PLANNED  EXPENDITURES  FOR 5
MONTHS.

THERE CAN BE NO ASSURANCE  THAT WE WILL BE SUCCESSFUL IN OUR EFFORTS TO CONCLUDE
THE ARP  TRANSACTION  OR ANY OTHER  TRANSACTION  TO OBTAIN OR BUILD A VIABLE AND
PROFITABLE BUSINESS, OR THAT WE WILL B E ABLE TO RAISE SUFFICIENT DEBT OR EQUITY
FINANCING TO DEVELOP OUR BUSINESS(S).

                                       27
<PAGE>
RESULTS OF OPERATIONS

At June 30, 2004, we had a working  capital  deficiency of $40,287,  compared to
working capital of $20 at September 30, 2003.

At June 30,  2004,  we had $nil  assets.  This  compares  with  total  assets at
September 30, 2003 of $20, which was comprised solely of cash.

Revenues  were -0- for the nine  months and the third  quarter  ending  June 30,
2004, and -0- for the  comparable  periods in 2003.  General and  administrative
expenses  were $40,307 for the nine months ended June 30, 2004 versus $3,821 for
the same period in 2003. For the third quarter ended June 30, 2004,  general and
administrative  expenses were $39,201 and $1,475 in 2003.  Expenses for the 2004
third quarter include  $37,500  payable to a consultant for services  related to
identification and assistance in consummating the transaction with ARP.

We have not had revenues from  inception.  Our company has no assets and without
additional  capital,  we may not be able to  survive  beyond  the next  quarter.
Although  there may be  insufficient  capital to execute our business  plan,  we
expect to survive  with funding  from sales of  securities  and, as necessary or
from shareholder  loans.  There is no assurance we will be successful in raising
the necessary funding or on terms that are acceptable to our company.

ITEM 3 - CONTROLS AND PROCEDURES

Our sole officer  evaluated the  effectiveness  of our  disclosure  controls and
procedures  (as defined in Rule 13a-14c under the Securities and Exchange Act of
1934,  as  amended)  within  90 days of the  filing  date of this Form 10-Q (the
Evaluation  Date).  Based  on that  evaluation,  he  concluded  that,  as of the
Evaluation   Date,  our  Company  had   sufficient   procedures  for  recording,
processing,  summarizing  and  reporting  information  that  is  required  to be
disclosed in its reports  under the  Securities  and  Exchange  Act of 1934,  as
amended.

Since the Evaluation  Date,  there have not been any significant  changes to our
internal  controls  or other  factors  that  could  significantly  affect  these
controls,   including  any   corrective   actions  with  regard  to  significant
deficiencies and material weaknesses.

                                       28
<PAGE>
                            PART II OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

None

ITEM 2. CHANGES IN SECURITIES

On May 28,  2004,  a 16.5 for 1 forward  split was  affected  with the  Delaware
Secretary of State of our issued and outstanding  Common Stock. As a result,  it
increased  from  3,411,000  shares  to  56,281,500  shares.  Additionally,   our
authorized Common Stock increased from 80,000,000  shares to 100,000,000  shares
(SEE ITEM 4). The forward split took effect with the OTC Bulletin  Board on June
8, 2004 under the new stock symbol SJOS. Our new CUSIP number is 798212 20 5.

On June 8, 2004, Mr. Greenwood, our former director,  tendered 32,284,988 shares
beneficially  held  by him  to  treasury  for  cancellation.  Subsequent  to the
cancellation,  there are 23,996,512 issued and outstanding  Common Shares in our
Company.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

On January 19, 2004,  our  company's  sole director  approved  Amendments to our
company's Certificate of Incorporation as follows:

     (i) an amendment to the Certificate of  Incorporation to change the name of
     our company to "Conquest Geoservices,  Inc." to more accurately reflect our
     company's proposed future business;

     (ii) an amendment to our Certificate of  Incorporation  to effect a forward
     split (the  "Forward  Split") of our company's  Common Stock  including the
     authorized  capital  increase  from  80,000,000  shares of Common  Stock to
     880,000,000  shares of Common  Stock and  correspondingly  the  issued  and
     outstanding  capital  increase  from  3,411,000  shares of Common  Stock to
     37,521,000 shares of Common Stock; and

     (iii) an amendment to our Certificate of Incorporation to create 20,000,000
     Class A Special Voting Shares.

On April 20, 2004,  we decided to  terminate  our efforts to pursue the proposed
acquisition  of  Conquest,  because it  appeared we would not be  successful  in
obtaining the necessary financing on a timely basis. Accordingly, as of the same
date,  our sole  director  passed a director's  resolution to declare that these
Proposed  Amendments  are  no  longer  advisable  and  that  we  will  not  seek
shareholders'  approval of the Proposed  Amendments.  Approval from shareholders
holding a majority of our Common Stock was never obtained, and we did not file a
Certificate of Amendment with the Secretary of State for the State of Delaware.

                                       29
<PAGE>
Concurrent with the termination of this proposed acquisition,  our sole director
approved the following resolutions and gave notice to our stockholders to:

     (i) effect a 16.5 to 1 forward  split (the  "Forward  Split") of our Common
     Stock,  such that our issued and  outstanding  Common Stock  increase  from
     3,411,000 shares to 56,281,500  shares, and our authorized capital increase
     from 80,000,000  shares of Common Stock and 20,000,000  shares of Preferred
     Stock to  1,320,000,000  shares of Common  Stock and  20,000,000  shares of
     Preferred Stock;

     (ii) reduce the authorized  share of our Common Stock following the Forward
     Split from  1,320,000,000  shares of Common Stock to 100,000,000  shares of
     Common Stock so that our authorized  capital consist of 100,000,000  shares
     of Common Stock.

On April 20,  2004,  the  shareholder  holding a majority  of our  Common  Stock
approved by way of a written consent  resolution an Amendment to the Certificate
of Incorporation to carry out the Forward Split and the subsequent  reduction of
the authorized shares of Common Stock.

The Forward Split and subsequent  reduction of the  authorized  shares of Common
Stock was affected with the Delaware Secretary of State on May 28, 2004.

ITEM 5. OTHER INFORMATION

In  conjunction  with the  transaction  with  ARP,  Mr.  Greenwood,  our  former
director,  sold 699,996 shares  beneficially held by him to an individual who is
intended to be a key employee of GammaCan.

On June 17, 2004,  Mr.  Christopher  Greenwood  resigned as our sole Officer and
Director,  and was  replaced  by Mr.  David  Stephens.  Mr.  Stephens  has  been
self-employed  as an independent  business  consultant  since 1999, and provides
consulting  services  in  the  areas  of  finance,   operations  and  regulatory
disclosure.  Previous to this,  he  provided  services to a number of public and
private  companies  conducting  business  in   telecommunications,   hydrocarbon
exploration and services, and biotechnology.  He has also served in an executive
capacity  for  several  publicly  listed  financial  institutions  and  emerging
technology companies.

Concurrent with the resignation of Mr. Greenwood, we relocated our operations to
Suite 1500, 800 West Pender Street, Vancouver,  B.C., Canada, V6C 2V6. Our phone
number is (780)  708-0495 and our fax number is (604)  605-1173.  We  anticipate
that we may relocate again upon closing of the transaction with ARP.

On July 5, 2004,  our  Director  adopted a  resolution  changing the name of our
Company to GammaCan International Inc., to better reflect our business. The name
change was approved by the consent of a majority of our stockholders,  which was
obtained on July 8, 2004.

                                       30
<PAGE>
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K

(a) Pursuant to Rule 601 of Regulation  SB, the following  exhibits are included
herein or incorporated by reference.

     3(i)  Articles of Incorporation *
     3(ii) Bylaws *
     10    Sale of Intellectual  Property  Agreement dated June 11, 2004 between
           Gammacan, Ltd. and ARP Biomed, Ltd. ***
     31.1  302 Certification of Chief Executive Officer
     32.1  906 Certification of Chief Executive Officer
     99    Certificate of Amendment of Certificate of Incorporation **
----------
*    Incorporated  by reference - refer to the  company's  initial  registration
     statement
**   Incorporated by reference - refer to the company's 8-K filed June 8, 2004
***  Incorporated by reference - refer to the company's 8-K filed June 22, 2004

(b) Reports on Form 8-K

April  27,  2004  reporting  the  termination  of  a  proposed  acquisition  and
amendments to the company's Articles of Incorporation

June 8, 2004  reporting  the 16.5 for 1 forward  split of the  Company's  issued
Common Stock and the net increase in the  Company's  authorized  Common Stock by
20,000,000 shares

June 22, 2004 reporting the change of address for the Company,  the  resignation
and  appointment  of the Company's  sole officer and director,  cancellation  of
32,284,988 Common Shares, and the acquisition of intellectual  property from ARP
Biomed, Ltd.

                                   SIGNATURES

Pursuant to the  requirements  of Section 12 of the  Securities  Exchange Act of
1934, the Company has duly caused this disclosure  statement to be signed on its
behalf by the undersigned, thereunto duly authorized.

SAN JOSE INTERNATIONAL, INC.

Date: July 23, 2004


By: /s/ David Stephens
-----------------------------
David Stephens, President

                                       31